Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study
Titel:
Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study
Auteur:
Crowley, Jeffrey J. Langley, Richard G. Gordon, Kenneth B. Pinter, Andreas Ferris, Laura K. Rubant, Simone Photowala, Huzefa Xue, Zhenyi Wu, Tianshuang Zhan, Tianyu Beeck, Stefan Shah, Megha Warren, Richard B.